文献速递糖尿病肥胖与代谢综合征

恩格列净对阻塞性睡眠呼吸暂停及心血管肾脏结局的影响:EMPA-REG OUTCOME试验探索性分析

The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
PubMed 文献 · Diabetes Care · 2020-10-01

本研究为EMPA-REG OUTCOME试验的探索性分析,纳入7020例2型糖尿病合并心血管疾病患者,评估恩格列净对阻塞性睡眠呼吸暂停(OSA)发病率及代谢、心血管和肾脏结局的影响。结果显示,基线OSA患者合并症更多且心血管肾脏事件发生率更高;恩格列净在有无OSA患者中均显著降低结局风险,并可能减少新发OSA风险(HR 0.48)。

要点

  • 基线OSA患病率5.6%,OSA患者男性及中重度肥胖比例更高。
  • 恩格列净在有无OSA患者中均显著降低心血管和肾脏结局风险(交互P均>0.05)。
  • 恩格列净可能降低新发OSA风险(HR 0.48,95%CI 0.27-0.83)。

核心结论

  • 恩格列净在有无基线OSA患者中均对心血管和肾脏结局有保护作用,并可能减少新发OSA风险。

研究设计与样本

  • EMPA-REG OUTCOME试验的探索性分析,纳入7020例2型糖尿病合并心血管疾病患者,随机接受恩格列净10mg或25mg或安慰剂每日一次。

主要发现

  • 基线OSA报告率为5.6%(391/7020),OSA患者男性占83%、BMI≥35 kg/m2者占55%。
  • 中位随访3.1年,安慰剂组中基线OSA患者的心血管死亡、心衰住院及肾病发生率较无OSA者高1.2-2.0倍。
  • 恩格列净在有无OSA患者中均显著降低3点主要不良心血管事件、心血管死亡、心衰住院及肾病风险(交互P均>0.05)。
  • 恩格列净对体重的影响在OSA患者中更大(第52周校正均值差:OSA -2.9±0.5 kg vs 无OSA -1.9±0.1 kg)。

临床怎么用

  • 对于2型糖尿病合并心血管疾病患者,无论是否合并OSA,恩格列净均可带来心血管和肾脏获益。
  • 恩格列净可能有助于降低新发OSA风险,但需进一步研究验证。

局限性

  • OSA基于研究者报告,可能存在漏诊或误分类。
  • 探索性分析,新发OSA事件数较少,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its effects on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA in the EMPA-REG OUTCOME trial. RESEARCH DESIGN AND METHODS: Participants with diabetes and CV disease were randomized to empagliflozin (10 and 25 mg) or placebo daily in addition to standard of care. OSA was assessed by investigator report using Medical Dictionary for Regulatory Activities version 18.0, and CV outcomes were independently adjudicated. Analyses were performed using multivariable-adjusted Cox regression models. RESULTS: OSA was reported in 391 of 7,020 (5.6%) participants at baseline. Those with OSA were more likely to be male (83% vs. 71%) and to have moderate to severe obesity (BMI ≥35 kg/m2; 55% vs. 18%). Over a median of 3.1 years, empagliflozin had similar placebo-adjusted reductions in HbA1c, waist circumference, and systolic blood pressure, regardless of OSA status, but a larger effect on weight (adjusted mean ± SE difference at week 52: OSA vs. no OSA -2.9 ± 0.5 vs. -1.9 ± 0.1 kg). Incidence of 3-point major adverse CV events, CV death, heart failure hospitalization, and incident or worsening nephropathy in the placebo group was 1.2- to 2.0-fold higher for those with baseline OSA compared with those without. Empagliflozin significantly reduced the risk for outcomes regardless of OSA status (P-interaction all >0.05). Fifty patients reported a new diagnosis of OSA through 7 days after medication discontinuation, and this occurred less often with empagliflozin treatment (hazard ratio 0.48 [95% CI 0.27, 0.83]). CONCLUSIONS: In EMPA-REG OUTCOME, participants with OSA had greater comorbidity and higher frequency of CV and renal events. Empagliflozin had favorable effects on risk factors and CV and renal outcomes regardless of preexisting OSA and may also reduce the risk for new-onset OSA.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Neeland IJ, Eliasson B, Kasai T, et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020. PMID: 33004464. doi:10.2337/dc20-1096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。